Shares of Dimension Therapeutics, Inc. (NASDAQ:DMTX) have been given an average recommendation of “Buy” by the seven analysts that are covering the stock. Two equities research analysts have rated the stock with a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $12.08.

Several research analysts have recently weighed in on DMTX shares. Zacks Investment Research raised shares of Dimension Therapeutics from a “hold” rating to a “strong-buy” rating and set a $5.50 price objective for the company in a report on Friday. Canaccord Genuity set a $20.00 target price on shares of Dimension Therapeutics and gave the company a “buy” rating in a research report on Wednesday, December 14th. Finally, Jefferies Group started coverage on shares of Dimension Therapeutics in a research report on Friday, November 11th. They set a “buy” rating and a $12.00 target price for the company.

COPYRIGHT VIOLATION WARNING: This story was first reported by Watch List News and is the propert of of Watch List News. If you are accessing this story on another publication, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at http://www.watchlistnews.com/dimension-therapeutics-inc-dmtx-receives-13-40-consensus-target-price-from-brokerages/1061103.html.

Shares of Dimension Therapeutics (NASDAQ:DMTX) opened at 4.80 on Wednesday. The stock’s market cap is $120.21 million. Dimension Therapeutics has a 52-week low of $4.00 and a 52-week high of $10.47. The stock’s 50 day moving average is $4.45 and its 200 day moving average is $6.25.

Institutional investors have recently bought and sold shares of the company. Teachers Advisors Inc. raised its position in Dimension Therapeutics by 224.3% in the second quarter. Teachers Advisors Inc. now owns 19,204 shares of the company’s stock worth $115,000 after buying an additional 13,283 shares during the last quarter. Highbridge Capital Management LLC purchased a new position in Dimension Therapeutics during the second quarter worth $123,000. Bridgeway Capital Management Inc. purchased a new position in Dimension Therapeutics during the second quarter worth $128,000. Credit Suisse AG raised its position in Dimension Therapeutics by 16.5% in the third quarter. Credit Suisse AG now owns 16,488 shares of the company’s stock worth $132,000 after buying an additional 2,332 shares during the last quarter. Finally, A.R.T. Advisors LLC purchased a new position in Dimension Therapeutics during the second quarter worth $134,000. Institutional investors and hedge funds own 85.18% of the company’s stock.

About Dimension Therapeutics

Dimension Therapeutics, Inc is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa).

5 Day Chart for NASDAQ:DMTX

Receive News & Ratings for Dimension Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dimension Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.